Cargando…
rAAV-delivered PTEN therapeutics for prostate cancer
Effective treatments for prostate cancer (PCa) require further development, and previous studies have reported that PTEN and its downstream target CDKN1B are significantly downregulated in PCa cells compared with normal cells. Therefore, modulation of PTEN and CDKN1B expression might be a promising...
Autores principales: | Ai, Jianzhong, Li, Jia, Su, Qin, Ma, Hong, Wei, Qiang, Li, Hong, Gao, Guangping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671520/ https://www.ncbi.nlm.nih.gov/pubmed/34976432 http://dx.doi.org/10.1016/j.omtn.2021.11.018 |
Ejemplares similares
-
Transcriptome Profiling of Neovascularized Corneas Reveals miR-204 as a Multi-target Biotherapy Deliverable by rAAVs
por: Lu, Yi, et al.
Publicado: (2018) -
Durability of transgene expression after rAAV gene therapy
por: Muhuri, Manish, et al.
Publicado: (2022) -
MicroRNA-regulated, Systemically Delivered rAAV9: A Step Closer to CNS-restricted Transgene Expression
por: Xie, Jun, et al.
Publicado: (2011) -
Robust Long-term Transduction of Common Marmoset Neuromuscular Tissue With rAAV1 and rAAV9
por: Okada, Hironori, et al.
Publicado: (2013) -
rAAV8 and rAAV9-Mediated Long-Term Muscle Transduction with Tacrolimus (FK506) in Non-Human Primates
por: Ishii, Akiko, et al.
Publicado: (2020)